Medline Industries has initiated a correction of convenience kits containing recalled Bupivacaine Hydrochloride in Dextrose Injection components, according to a US Food and Drug Administration alert issued this week. The action follows an earlier recall of the anesthetic product manufactured by Huons Co. Ltd.
Key takeaways
- Medline is removing recalled Bupivacaine Hydrochloride in Dextrose Injection components from affected convenience kits
- The correction addresses recalled components manufactured by Huons Co. Ltd
- Healthcare facilities should identify and remove affected kits from inventory
Correction Details and Scope
The FDA’s device correction alert specifies that Medline is addressing convenience kits that contain the recalled bupivacaine components. Bupivacaine hydrochloride is a local anesthetic commonly used in surgical procedures and pain management.
The original recall involved Huons Bupivacaine Hydrochloride in Dextrose Injection, USP, prompting Medline to take corrective action for any convenience kits containing these components. Healthcare facilities using Medline convenience kits should verify their inventory for affected products.
Clinical Impact and Safety Measures
Convenience kits are pre-assembled collections of medical supplies commonly used in healthcare settings to streamline procedures. When components within these kits are subject to recall, manufacturers must either recall the entire kit or implement corrections to remove the problematic components.
The Centers for Disease Control and Prevention emphasizes the importance of robust supply chain safety measures in healthcare settings. Healthcare providers should establish protocols for identifying and managing recalled medical products within their facilities.
Convenience kit corrections require systematic removal of recalled components while maintaining the integrity of remaining kit contents
— FDA Medical Device Safety Guidelines
What this means
Frequently asked questions
What is a convenience kit correction?
A convenience kit correction involves removing specific recalled components from pre-assembled medical kits while leaving other components intact. This allows the remaining kit contents to continue being used safely.
How should healthcare facilities respond?
Healthcare facilities should identify affected Medline convenience kits in their inventory and follow the manufacturer’s instructions for the correction process. They should also establish protocols for managing future product recalls.
What was wrong with the bupivacaine injection?
The specific issues with the Huons Bupivacaine Hydrochloride in Dextrose Injection that led to the original recall were detailed in the FDA’s initial recall notice. Healthcare providers should refer to that notice for complete information.
This correction demonstrates the medical device industry’s multi-layered approach to product safety, where downstream manufacturers take responsibility for addressing recalled components in their products. For more updates on medical device safety, visit our Quality & Safety coverage.
Was this article helpful?
Related Coverage
